Dynasil Delivers Pilot Production Order for Proprietary Radiation Detection Technology to Thermo Fisher Scientific
Dynasil's Gamma-Neutron Scintillator Integrated into Thermo Fisher Scientific's Market-Leading Personal Radiation Detectors
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dynasil Corporation of America (NAS: DYSL) today announced that Thermo Fisher Scientific Inc. (NYS: TMO) is integrating the Company's proprietary gamma and neutron scintillator detection technology, known as CLYC, into the Thermo Fisher Scientific RadEye® GN+ Personal Radiation Detector. The device is being deployed to homeland security, defense and law enforcement agencies worldwide.
The CLYC dual mode scintillator has been successfully commercialized through Dynasil's RMD and Hilger Crystals business units. The technology is capable of detecting nuclear and radioactive materials in all environments and can be used for both nuclear weapons detection and civilian radiation leak detection. Developed by the Company's RMD, Inc. business unit with funding from multiple U.S. Government agencies, CLYC is the first dual mode (gamma and neutron) scintillation detector commercialized for homeland security and defense applications.
"Our CLYC technology simultaneously detects potentially harmful gamma-ray sources and neutron-emitting elements while eliminating the need to use scarce Helium-3 gas as their detection medium," stated Dynasil Chairman, Interim President and Chief Executive Officer Peter Sulick. "The ability to measure two radiation sources with a single detector not only provides significant cost benefits; it also saves valuable time by enabling first responders to rapidly and more accurately detect a broader range of potential threats."
Dynasil Corporation of America (NAS: DYSL) develops and manufactures detection and analysis technology, precision instruments and optical components for the homeland security, medical and industrial markets. Combining world-class technology with expertise in research and materials science, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications, probes for medical imaging and sensors for non-destructive testing. Dynasil has an impressive and growing portfolio of issued and pending U.S. patents. The Company is based in Watertown, Massachusetts, with additional operations in Mass., Minn., NY, NJ and the United Kingdom. More information about the Company is available at www.dynasil.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $12 billion, we have approximately 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity™ Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit www.thermofisher.com.
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management.These forward-looking statements may be identified by the use of words such as "may," "could," "expect," "estimate," "anticipate," "continue" or similar terms, though not all forward-looking statements contain such words.The actual results of the future events described in such forward-looking statements could differ materially from those stated in such forward-looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to develop and commercialize our products, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, competition, the loss of key management personnel, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to identify and execute on acquisition opportunities and integrate such acquisitions into our business, and seasonality, as well as the uncertainties set forth in the Company's Annual Report on Form 10-Kand from time to time in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
KEYWORDS: United States North America Massachusetts
The article Dynasil Delivers Pilot Production Order for Proprietary Radiation Detection Technology to Thermo Fisher Scientific originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.